Cero Therapeutics to present data on CER-1236 at SITC conference

CERo Therapeutics (CERO) will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer conference being held November 5-9, 2025 in National Harbor, Md. The poster, titled, “CER-1236, an investigational T cell product targeting TIM-4 Ligand, exhibits sustained effector function and resistance to exhaustion,” highlights preclinical data showing the durability of activity for CER-1236. Data demonstrates sustained cell expansion across multiple rounds of antigen stimulation in combination with a robust cytokine response, compared to CD3/CD28 polyclonal stimulation, which induced strong initial activation, but led to cell exhaustion. CERo CEO Chris Ehrlich said, “We believe these data are supportive of what we have seen in broad terms in our Phase 1 trial, while providing additional insight that we believe will be useful as we continue development. SITC is a prestigious conference in the space, and we are grateful for the continued recognition for our science.” The Company is currently conducting the first-in-human, multi-center, open label, Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML. The two-part study initiated with dose escalation to determine the highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events and serious adverse events incidence of dose limited toxicities and estimation of overall response rate, complete response, composite complete response, and measurable residual disease. Secondary outcome measures include pharmacokinetics.